Stay updated with breaking news from Mark Sumeray. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eneboparatide is an investigational parathyroid hormone receptor 1 (PTHR1) agonist that works by binding with high affinity to a specific conformation of the PTH1 receptor.
Amolyt Pharma to Host Hybrid Key Opinion Leader Event on Eneboparatide, a PTHR1 Agonist Entering Phase 3 for the Treatment of Hypoparathyroidism, in Chicago on June 16, 2023LYON, France and CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic pepti...
LYON, France and CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced
LYON, France and CAMBRIDGE, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today
Presentation highlights results from 13- and 39-week studies of eneboparatide in non-human primates demonstrating no evidence of deleterious impact on bone quantity or quality as measured by multiple bone